PTC Therapeutics, Inc.

Total Valuation

PTC Therapeutics, Inc. carries a market capitalization of 6.81B, placing it among publicly traded companies globally. Its enterprise value stands at 3.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

PTC Therapeutics, Inc. currently has 82.88M shares outstanding.

Valuation Ratios

PTC Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 21.16. The price-to-sales ratio is 6.59, and the price-to-book ratio stands at -1.84.

Enterprise Valuation

On an enterprise value basis, PTC Therapeutics, Inc. trades at an EV/EBITDA multiple of 13.88 and an EV/FCF ratio of 18.52. The EV/Sales ratio of 4.78 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.44 provides insight into valuation relative to core operating earnings.

Financial Position

PTC Therapeutics, Inc. maintains a current ratio of 2.44, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -218.93, indicating conservative leverage, while an interest coverage ratio of -0.12 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

PTC Therapeutics, Inc.'s stock has gained approximately 65.58468% over the past 52 weeks. The 50-day moving average sits at 71.23, while the 200-day moving average is 70.41.

Income Statement

Over the trailing twelve months, PTC Therapeutics, Inc. generated 827.11M in revenue and converted that into -186.73M in net income, yielding earnings per share of -2.27. EBITDA reached -20.10M, while operating income came in at -67.11M.

Balance Sheet

PTC Therapeutics, Inc. holds 1.89B in cash and equivalents against 395.09M in total debt, resulting in a net debt position of -547.05M. Total book value stands at -2.97B, with working capital of 1.33B providing operational flexibility.

Cash Flow

PTC Therapeutics, Inc. produced -217.95M in operating cash flow over the past twelve months. After subtracting -298.83M in capital expenditures, free cash flow totaled -516.78M - equivalent to -6.46 per share.

Margins

PTC Therapeutics, Inc. operates with a gross margin of 92.48, reflecting its pricing power and cost economics. The operating margin of -8.11 and net profit margin of -22.58 provide insight into operational efficiency.

Dividends & Yields

Scores

PTC Therapeutics, Inc. posts an Altman Z-Score of 0.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.